Skip to main content
. 2019 Dec 10;11(23):11659–11672. doi: 10.18632/aging.102570

Figure 3.

Figure 3

NiCl2 activates MAPKs and IRF3 pathway in BMDMs. (A and B) BMDMs are treated with NiCl2 (0, 0.1, 0.5 and 1.0 mM) for 24h, and immunoblotted for the whole cell lysis p-p38, p38, p-JNK, JNK, p-ERK and ERK protein expression. (C and D) BMDMs are treated with NiCl2 (0, 0.1, 0.5 and 1.0 mM) for 24h, and immunoblotted for the p-IRF3 and IRF3 protein expression. Data are presented with the means ± standard deviation (n=5). *p < 0.05 and **p < 0.01, compared with the control group.